Follow
ali m harandi
ali m harandi
Unknown affiliation
Verified email at gu.se
Title
Cited by
Cited by
Year
Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens
NPH Knudsen, A Olsen, C Buonsanti, F Follmann, Y Zhang, RN Coler, ...
Scientific reports 6 (1), 19570, 2016
2392016
Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA
J Holmgren, J Adamsson, F Anjuère, J Clemens, C Czerkinsky, ...
Immunology letters 97 (2), 181-188, 2005
2352005
A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection
AM Harandi, K Eriksson, J Holmgren
Journal of virology 77 (2), 953-962, 2003
2162003
Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens
F Wegmann, KH Gartlan, AM Harandi, SA Brinckmann, M Coccia, ...
Nature biotechnology 30 (9), 883-888, 2012
2132012
Differential roles of B cells and IFN-γ-secreting CD4+ T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice
AM Harandi, B Svennerholm, J Holmgren, K Eriksson
Journal of General Virology 82 (4), 845-853, 2001
1642001
Vaccine adjuvants: a priority for vaccine research
AM Harandi, D Medaglini, RJ Shattock, WG convened by EUROPRISE
Vaccine 28 (12), 2363-2366, 2010
1382010
Vaccine adjuvants: scientific challenges and strategic initiatives
AM Harandi, G Davies, OF Olesen
Expert review of vaccines 8 (3), 293-298, 2009
1142009
Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of …
AM Harandi, B Svennerholm, J Holmgren, K Eriksson
Journal of Virology 75 (14), 6705-6709, 2001
1142001
The mucosal adjuvant effect of α-galactosylceramide for induction of protective immunity to sexually transmitted viral infection
M Lindqvist, J Persson, K Thörn, AM Harandi
The Journal of Immunology 182 (10), 6435-6443, 2009
892009
Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 …
S Tengvall, A Lundqvist, RJ Eisenberg, GH Cohen, AM Harandi
Journal of virology 80 (11), 5283-5291, 2006
862006
Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA
J Holmgren, AM Harandi, C Czerkinsky
Expert review of vaccines 2 (2), 205-217, 2003
862003
Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study
A Huttner, ST Agnandji, C Combescure, JF Fernandes, EB Bache, ...
The Lancet Infectious Diseases 18 (7), 738-748, 2018
812018
Molecular signatures of vaccine adjuvants
T Olafsdottir, M Lindqvist, AM Harandi
Vaccine 33 (40), 5302-5307, 2015
752015
Orally administered CpG oligodeoxynucleotide induces production of CXC and CC chemokines in the gastric mucosa and suppresses bacterial colonization in a mouse model of …
S Raghavan, J Nystrom, M Fredriksson, J Holmgren, AM Harandi
Infection and immunity 71 (12), 7014-7022, 2003
752003
Single-cell BCR and transcriptome analysis after influenza infection reveals spatiotemporal dynamics of antigen-specific B cells
NR Mathew, JK Jayanthan, IV Smirnov, JL Robinson, H Axelsson, ...
Cell reports 35 (12), 2021
702021
Intranasal immunization with a proteoliposome-derived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice
J Del Campo, M Lindqvist, M Cuello, M Bäckström, O Cabrerra, J Persson, ...
Vaccine 28 (5), 1193-1200, 2010
632010
CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections.
AM Harandi, J Holmgren
Current opinion in investigational drugs (London, England: 2000) 5 (2), 141-145, 2004
632004
A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa
A Huttner, C Combescure, S Grillet, MC Haks, E Quinten, C Modoux, ...
Science translational medicine 9 (385), eaaj1701, 2017
582017
Comparative systems analyses reveal molecular signatures of clinically tested vaccine adjuvants
TA Olafsdottir, M Lindqvist, I Nookaew, P Andersen, J Maertzdorf, ...
Scientific Reports 6 (1), 39097, 2016
562016
Immunity against HIV/AIDS, malaria, and tuberculosis during co-infections with neglected infectious diseases: recommendations for the European Union research priorities
D Boraschi, M Abebe Alemayehu, A Aseffa, F Chiodi, J Chisi, G Del Prete, ...
PLoS Neglected Tropical Diseases 2 (6), e255, 2008
552008
The system can't perform the operation now. Try again later.
Articles 1–20